NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series

The approval of larotrectinib and entrectinib for cancer patients harboring an NTRK gene fusion has represented a milestone in the era of “histology-agnostic” drugs. Among the clinical trials that led to the approval of these two drugs, most of the enrolled patients were affected by soft tissue sarc...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannantuono, Giovanni Maria, Riondino, Silvia, Sganga, Stefano, Rosenfeld, Roberto, Guerriero, Simona, Carlucci, Manuela, Capotondi, Barbara, Torino, Francesco, Roselli, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695027/
https://www.ncbi.nlm.nih.gov/pubmed/36579526
http://dx.doi.org/10.3390/jpm12111819

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695027/
https://www.ncbi.nlm.nih.gov/pubmed/36579526
http://dx.doi.org/10.3390/jpm12111819

Ejemplares similares